The combination of a strong revenue beat, raised guidance, positive free cash flow inflection, and the BARDA award creates a powerful bullish catalyst. Watch for continued MACI implant growth and MHRA submission progress in 2026 as next catalysts. The stock should re-rate higher given the cash flow inflection and raised outlook.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $35.13entry
- T+1 · 6mo ago −4.75%α −5.58% · $33.46
- T+5 · 6mo ago −6.52%α −8.02% · $32.84
- T+20 · 6mo ago −1.11%α −4.25% · $34.74
- T+60 · 4mo ago +31.08%α +27.25% · $46.05
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Vericel reported Q1 2026 revenue of $68.4M (+30% YoY) and GAAP EPS of -$0.12 (vs consensus -$0.16, a 25% beat on the loss). The company raised full-year 2026 revenue guidance by $10M to $326-336M, driven by 22% MACI growth and 91% Burn Care growth. Free cash flow turned positive at $15.1M vs -$7.6M a year ago, signaling an inflection in cash generation.
Key Financial Metrics
Key Facts
- Total revenue $68.4M (+30% YoY), above consensus $63.6M
- GAAP EPS -$0.12 vs consensus -$0.16 (25% beat on loss)
- MACI revenue $56.4M (+22% YoY), Burn Care $12.0M (+91% YoY)
- Gross margin 72% vs 69% a year ago
- Adjusted EBITDA $9.6M (+195% YoY), 14% of revenue
- Operating cash flow $16.4M, free cash flow $15.1M (vs -$7.6M Q1 2025)
- FY2026 revenue guidance raised to $326-336M from $316-326M
- BARDA award up to $197M for NexoBrid procurement and development
- FDA approval for MACI commercial manufacturing at new facility
- Cash and investments $211M, no debt
Financial Impact
Revenue beat by ~$4.8M (7.5% above consensus), EPS beat by $0.04 on loss. Guidance raised by $10M at midpoint. Free cash flow swing of +$22.7M YoY.
Risk Factors
- GAAP net loss persists at -$6.3M despite operational improvements
- Selling expenses increased to $49.2M (+18% YoY) as sales force expands
- Dependence on MACI for ~82% of revenue concentration risk
- Geopolitical risks to NexoBrid supply from MediWound in Israel
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3289900 |
Track record
30 reports on VCEL
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.96 Now $57.48 +0.91% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 1/10 Entry $57.42 Now $57.48 +0.10% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $59.03 Now $57.48 −2.63% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $58.39 Now $57.48 −1.56% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $54.62 Now $57.48 +5.24% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers